AICentralResources
AI Tool Comparison

Comparing as AI Medical Research & Clinical Decision Support
PathAI vs Nabla

PathAI

PathAI

VS
Nabla

Nabla

Verdict by Category

Detailed category analysis is not available for this comparison.
View PathAI View Nabla

Detailed Comparison

Feature
PathAI
Nabla
Pricing
EnterprisePathAI operates exclusively on enterprise contracts with hospitals, pathology labs, and biopharma companies — there is no published pricing or self-serve access. Following its acquisition by Roche in May 2026, PathAI's commercial and contract terms are managed through Roche's diagnostics division. Clinical lab engagements use AISight for digital pathology workflow integration and AI algorithm deployment. Biopharma partnerships are structured as research service contracts for clinical trial tissue analysis, biomarker discovery, and companion diagnostic development. Contact PathAI or Roche Diagnostics to explore enterprise and research partnership options.
FreemiumNabla does not publish exact pricing on its official website; the primary calls-to-action are a free trial (via app.nabla.com) and "Talk to our team" for enterprise sales. Third-party sources consistently report a free tier with usage limits, with paid individual/clinician plans starting around $119/month per provider and higher tiers reported near $239/month per provider. Larger health-system deployments — Nabla's core market, spanning 130+ organizations — are sold via custom enterprise contracts with volume-based pricing, with independent estimates placing typical enterprise rates in the $150-$400/month per provider range depending on scale, EHR integration depth, and features. Exact costs require a sales conversation with Nabla.
Categories
AI Healthcare ToolsAI Research & Education Tools
AI Healthcare ToolsAI Productivity ToolsAI Developer APIs & Platforms
Summary
AI-powered digital pathology platform for oncology diagnostics and biopharma R&D — now part of Roche
Ambient AI that turns patient visits into clinical notes, dictation, and coding — right inside the EHR
PathAI

PathAI Pros & Cons

Pros

  • Acquired by Roche (May 2026) — now backed by the world's largest diagnostics company
  • 32.5M+ expert annotations — one of the world's largest pathology AI training datasets
  • 20+ AI algorithms covering oncology, liver disease, and tumor microenvironment analysis
  • AISight is scanner-neutral — works with Leica, Hamamatsu, Philips scanners with FDA clearance
  • CLIA-certified lab services for biopharma clinical trial support
  • Partnerships with BMS, Merck, Moffitt Cancer Center, and University Hospital Zurich
  • First AI pathology company recognized as a leader in CB Insights Digital Pathology market map

Cons

  • Acquired by Roche in May 2026 — future product roadmap and independent operations may change
  • Enterprise and biopharma-focused — not accessible to independent pathologists or small labs
  • No self-serve pricing or trial — all engagements are through enterprise procurement
  • Requires digital pathology infrastructure (scanners, storage, LIS integration)
  • Integration complexity for labs not yet on digital pathology workflows
Nabla

Nabla Pros & Cons

Pros

  • Fast note generation, roughly five seconds, that closely mirrors real clinical documentation in independent tests
  • Deep native integration with Epic and other major EHRs rather than copy-paste workflows
  • Broad specialty and language coverage suited to large, diverse health systems
  • Strong compliance posture (HIPAA, SOC 2 Type 2, ISO 27001, GDPR) with configurable data retention
  • Backed by peer-reviewed evidence, including a NEJM AI randomized trial showing documentation-time reductions
  • Combines documentation, dictation, and coding in one platform instead of separate point tools

Cons

  • Pricing isn't published; individuals and smaller practices must go through a sales conversation or rely on third-party estimates to budget
  • Primarily built for hospitals and health systems, so solo clinicians and small practices may find it less tailored than SMB-focused scribes
  • Relies on ambient recording, so encounters where a patient or clinician can't or won't be recorded aren't well supported
  • Some independent reviews note limited customization and quality drop-off on complex, multi-problem visits
  • Mobile app store ratings are mixed and based on a relatively small number of reviews compared to the platform's overall clinician base